antibiot
type
antimicrobi
substanc
activ
bacteria
import
type
antibacteri
agent
fight
bacteri
infect
antibiot
medic
wide
use
treatment
prevent
infect
kill
inhibit
growth
bacteria
limit
number
antibiot
possess
antiprotozo
activ
antibiot
effect
virus
common
cold
influenza
drug
inhibit
virus
term
antivir
drug
antivir
antibiot
sometim
term
antibiot
mean
oppos
life
base
greek
root
ἀντι
anti
βίος
biotic
life
broad
use
refer
ani
substanc
use
microb
usual
medic
usag
antibiot
penicillin
produc
natur
one
microorgan
fight
anoth
wherea
nonantibiot
antibacteri
sulfonamid
antisept
fulli
synthet
howev
class
goal
kill
prevent
growth
microorgan
includ
antimicrobi
chemotherapi
antibacteri
includ
antisept
drug
antibacteri
soap
chemic
disinfect
wherea
antibiot
import
class
antibacteri
use
specif
medicin
sometim
livestock
feed
evid
antibiot
use
sinc
ancient
time
mani
civil
use
topic
applic
mouldi
bread
mani
refer
benefici
effect
aris
ancient
egypt
china
serbia
greec
rome
person
direct
document
use
mould
treat
infect
john
parkinson
1567
1650
antibiot
truli
revolution
medicin
20th
centuri
alexand
fleme
1881
1955
discov
modern
day
penicillin
1928
realiz
great
potenti
penicillin
fleme
pursu
challeng
market
translat
commerci
use
help
biochemist
penicillin
final
avail
widespread
use
signific
benefici
dure
wartim
unfortun
did
n't
long
resist
begin
effect
easi
access
led
overus
bacteria
develop
resist
led
widespread
problem
world
health
organ
classifi
antimicrobi
resist
threat
longer
predict
futur
happen
right
everi
region
world
potenti
affect
anyon
ani
age
ani
countri
medic
use
antibiot
use
treat
prevent
bacteri
infect
sometim
protozoan
infect
metronidazol
effect
number
parasit
diseas
infect
suspect
respons
ill
respons
pathogen
identifi
empir
therapi
adopt
involv
administr
broad-spectrum
antibiot
base
sign
symptom
present
initi
pend
laboratori
result
sever
day
respons
pathogen
microorgan
alreadi
known
identifi
definit
therapi
start
usual
involv
use
narrow-spectrum
antibiot
choic
antibiot
given
base
cost
identif
critic
import
reduc
cost
toxic
antibiot
therapi
reduc
possibl
emerg
antimicrobi
resist
avoid
surgeri
antibiot
given
non-compl
acut
append
antibiot
given
prevent
measur
usual
limit
at-risk
popul
weaken
immun
particular
hiv
case
prevent
pneumonia
immunosuppress
drug
cancer
patient
surgeri
use
surgic
procedur
help
prevent
infect
incis
import
role
dental
antibiot
prophylaxi
use
prevent
bacteremia
consequ
infect
endocard
antibiot
use
prevent
infect
case
neutropenia
particular
cancer-rel
administr
mani
differ
rout
administr
antibiot
treatment
antibiot
usual
taken
mouth
sever
case
particular
deep-seat
infect
antibiot
given
intraven
inject
site
infect
easili
access
antibiot
given
topic
form
eye
drop
conjunctiva
conjunct
ear
drop
ear
infect
acut
case
swimmer
ear
topic
use
one
treatment
option
skin
condit
includ
acn
cellul
advantag
topic
applic
includ
achiev
high
sustain
concentr
antibiot
site
infect
reduc
potenti
absorpt
toxic
total
volum
antibiot
requir
reduc
therebi
reduc
risk
antibiot
misus
topic
antibiot
appli
certain
type
surgic
wound
report
reduc
risk
surgic
site
infect
howev
certain
general
caus
concern
topic
administr
antibiot
absorpt
antibiot
occur
quantiti
antibiot
appli
difficult
accur
dose
possibl
local
hypersensit
reaction
contact
dermat
occur
preval
antibiot
consumpt
vari
wide
countri
‘
report
surveil
antibiot
consumpt
’
publish
2018
analys
2015
data
65
countri
measur
defin
daili
dose
1,000
inhabit
day
mongolia
highest
consumpt
rate
64.4
burundi
lowest
4.4
amoxicillin
amoxicillin/clavulan
acid
frequent
consum
side-effect
antibiot
screen
ani
negat
effect
befor
approv
clinic
use
usual
consid
safe
toler
howev
antibiot
associ
wide
extent
advers
effect
rang
mild
veri
sever
depend
type
antibiot
use
microb
target
individu
patient
effect
reflect
pharmacolog
toxicolog
properti
antibiot
involv
hypersensit
allerg
reaction
advers
effect
rang
fever
nausea
major
allerg
reaction
includ
photodermat
anaphylaxi
safeti
profil
newer
drug
establish
long
histori
use
common
side-effect
includ
diarrhea
result
disrupt
speci
composit
intestin
flora
result
exampl
overgrowth
pathogen
bacteria
clostridium
difficil
antibacteri
affect
vagin
flora
lead
overgrowth
yeast
speci
genus
candida
vulvo-vagin
area
addit
side-effect
result
interact
drug
possibl
tendon
damag
administr
quinolon
antibiot
corticosteroid
correl
obes
exposur
antibiot
earli
life
associ
increas
bodi
mass
human
mous
model
earli
life
critic
period
establish
intestin
microbiota
metabol
develop
mice
expos
subtherapeut
antibiot
treatment
stat
penicillin
vancomycin
chlortetracyclin
alter
composit
gut
microbiota
metabol
capabl
one
studi
report
mice
given
low-dos
penicillin
1
μg
/
g
bodi
weight
birth
wean
process
increas
bodi
mass
fat
mass
acceler
growth
increas
hepat
express
gene
involv
adipogenesi
compar
control
mice
addit
penicillin
combin
high-fat
diet
increas
fast
insulin
level
mice
howev
unclear
antibiot
caus
obes
human
studi
correl
earli
exposur
antibiot
<
6
month
increas
bodi
mass
10
20
month
anoth
studi
type
antibiot
exposur
signific
highest
risk
overweight
given
macrolid
compar
penicillin
cephalosporin
therefor
correl
antibiot
exposur
earli
life
obes
human
causal
relationship
remain
unclear
correl
antibiot
use
earli
life
obes
effect
antibiot
obes
human
need
weigh
benefici
effect
clinic
indic
treatment
antibiot
infanc
interact
birth
control
pill
well-control
studi
antibiot
use
increas
risk
oral
contracept
failur
major
studi
indic
antibiot
interfer
birth
control
pill
clinic
studi
suggest
failur
rate
contracept
pill
caus
antibiot
veri
low
1
situat
increas
risk
oral
contracept
failur
includ
non-compli
miss
pill
vomit
diarrhea
gastrointestin
disord
interpati
variabl
oral
contracept
absorpt
affect
ethinylestradiol
serum
level
blood
women
menstrual
irregular
higher
risk
failur
advis
use
backup
contracept
dure
antibiot
treatment
one
week
complet
patient-specif
risk
factor
reduc
oral
contracept
efficaci
suspect
backup
contracept
recommend
case
antibiot
suggest
affect
effici
birth
control
pill
broad-spectrum
antibiot
rifampicin
case
increas
activ
hepat
liver
enzym
caus
increas
breakdown
pill
activ
ingredi
effect
intestin
flora
result
reduc
absorpt
estrogen
colon
suggest
suggest
inconclus
controversi
clinician
recommend
extra
contracept
measur
appli
dure
therapi
use
antibiot
suspect
interact
oral
contracept
studi
possibl
interact
antibiot
birth
control
pill
oral
contracept
requir
care
assess
patient-specif
risk
factor
potenti
oral
contract
pill
failur
prior
dismiss
need
backup
contracept
alcohol
interact
alcohol
certain
antibiot
occur
caus
side-effect
decreas
effect
antibiot
therapi
moder
alcohol
consumpt
unlik
interfer
mani
common
antibiot
specif
type
antibiot
alcohol
consumpt
caus
side-effect
therefor
potenti
risk
side-effect
effect
depend
type
antibiot
administ
antibiot
metronidazol
tinidazol
cephamandol
latamoxef
cefoperazon
cefmenoxim
furazolidon
caus
disulfiram-lik
chemic
reaction
alcohol
inhibit
breakdown
acetaldehyd
dehydrogenas
result
vomit
nausea
short
breath
addit
efficaci
doxycyclin
erythromycin
succin
reduc
alcohol
consumpt
effect
alcohol
antibiot
activ
includ
alter
activ
liver
enzym
break
antibiot
compound
howev
red
wine
high
degre
polyphenol
demonstr
in-vitro
antibacteri
properti
pharmacodynam
success
outcom
antimicrobi
therapi
antibacteri
compound
depend
sever
factor
includ
host
defens
mechan
locat
infect
pharmacokinet
pharmacodynam
properti
antibacteri
bactericid
activ
antibacteri
depend
bacteri
growth
phase
requir
ongo
metabol
activ
divis
bacteri
cell
base
laboratori
studi
clinic
set
elimin
bacteri
infect
sinc
activ
antibacteri
depend
frequent
concentr
vitro
character
antibacteri
activ
common
includ
determin
minimum
inhibitori
concentr
minimum
bactericid
concentr
antibacteri
predict
clinic
outcom
antimicrobi
activ
antibacteri
usual
combin
pharmacokinet
profil
sever
pharmacolog
paramet
use
marker
drug
efficaci
combin
therapi
import
infecti
diseas
includ
tuberculosi
combin
therapi
i.e.
concurr
applic
two
antibiot
use
delay
prevent
emerg
resist
acut
bacteri
infect
antibiot
combin
therapi
prescrib
synergist
effect
improv
treatment
outcom
combin
effect
antibiot
better
individu
effect
methicillin-resist
staphylococcus
aureus
infect
treat
combin
therapi
fusid
acid
rifampicin
antibiot
use
combin
antagonist
combin
effect
two
antibiot
individu
antibiot
given
monotherapi
exampl
chloramphenicol
tetracyclin
antagonist
penicillin
aminoglycosid
howev
vari
depend
speci
bacteria
general
combin
bacteriostat
antibiot
bactericid
antibiot
antagonist
class
antibiot
common
classifi
base
mechan
action
chemic
structur
spectrum
activ
target
bacteri
function
growth
process
target
bacteri
cell
wall
penicillin
cephalosporin
cell
membran
polymyxin
interfer
essenti
bacteri
enzym
rifamycin
lipiarmycin
quinolon
sulfonamid
bactericid
activ
protein
synthesi
inhibitor
macrolid
lincosamid
tetracyclin
usual
bacteriostat
bactericid
aminoglycosid
categor
base
target
specif
narrow-spectrum
antibiot
target
specif
type
bacteria
gram-neg
gram-posit
wherea
broad-spectrum
antibiot
affect
wide
rang
bacteria
follow
40-year
break
discov
new
class
antibacteri
compound
four
new
class
antibiot
brought
clinic
use
late
2000s
earli
2010s
cyclic
lipopeptid
daptomycin
glycylcyclin
tigecyclin
oxazolidinon
linezolid
lipiarmycin
fidaxomicin
product
advanc
medicin
chemistri
modern
antibacteri
semisynthet
modif
various
natur
compound
includ
exampl
beta-lactam
antibiot
includ
penicillin
produc
fungi
genus
penicillium
cephalosporin
carbapenem
compound
isol
live
organ
aminoglycosid
wherea
antibacteri
—
exampl
sulfonamid
quinolon
oxazolidinon
—
produc
sole
chemic
synthesi
mani
antibacteri
compound
relat
small
molecul
molecular
weight
1000
dalton
sinc
pioneer
effort
howard
florey
chain
1939
import
antibiot
includ
antibacteri
medicin
led
intens
research
produc
antibacteri
larg
scale
follow
screen
antibacteri
wide
rang
bacteria
product
activ
compound
carri
use
ferment
usual
strong
aerob
condit
resist
emerg
resist
bacteria
antibiot
common
phenomenon
emerg
resist
reflect
evolutionari
process
place
dure
antibiot
therapi
antibiot
treatment
select
bacteri
strain
physiolog
genet
enhanc
capac
surviv
high
dose
antibiot
certain
condit
result
preferenti
growth
resist
bacteria
growth
suscept
bacteria
inhibit
drug
exampl
antibacteri
select
strain
previous
acquir
antibacterial-resist
gene
demonstr
1943
luria
delbrück
experi
antibiot
penicillin
erythromycin
use
high
efficaci
mani
bacteri
speci
strain
becom
effect
increas
resist
mani
bacteri
strain
resist
form
biodegred
pharmaceut
sulfamethazine-degrad
soil
bacteria
introduc
sulfamethazin
medic
pig
fece
surviv
bacteria
result
inherit
resist
growth
resist
antibacteri
occur
horizont
gene
transfer
horizont
transfer
like
happen
locat
frequent
antibiot
use
antibacteri
resist
impos
biolog
cost
therebi
reduc
fit
resist
strain
limit
spread
antibacterial-resist
bacteria
exampl
absenc
antibacteri
compound
addit
mutat
howev
compens
fit
cost
aid
surviv
bacteria
paleontolog
data
antibiot
antibiot
resist
ancient
compound
mechan
use
antibiot
target
mutat
negat
impact
bacteri
reproduct
viabil
sever
molecular
mechan
antibacteri
resist
exist
intrins
antibacteri
resist
genet
makeup
bacteri
strain
exampl
antibiot
target
absent
bacteri
genom
acquir
resist
result
mutat
bacteri
chromosom
acquisit
extra-chromosom
dna
antibacterial-produc
bacteria
evolv
resist
mechan
similar
transfer
antibacterial-resist
strain
spread
antibacteri
resist
occur
vertic
transmiss
mutat
dure
growth
genet
recombin
dna
horizont
genet
exchang
instanc
antibacteri
resist
gene
exchang
differ
bacteri
strain
speci
plasmid
carri
resist
gene
plasmid
carri
sever
differ
resist
gene
confer
resist
multipl
antibacteri
cross-resist
sever
antibacteri
occur
resist
mechan
encod
singl
gene
convey
resist
one
antibacteri
compound
antibacterial-resist
strain
speci
sometim
refer
superbug
contribut
emerg
diseas
control
exampl
emerg
bacteri
strain
caus
tuberculosi
resist
previous
effect
antibacteri
treatment
pose
mani
therapeut
challeng
everi
year
near
half
million
new
case
multidrug-resist
tuberculosi
mdr-tb
estim
occur
worldwid
exampl
ndm-1
newli
identifi
enzym
convey
bacteri
resist
broad
rang
beta-lactam
antibacteri
unit
kingdom
health
protect
agenc
state
isol
ndm-1
enzym
resist
standard
intraven
antibiot
treatment
sever
infect
26
2016
e
coli
bacteria
superbug
identifi
unit
state
resist
colistin
line
defenc
antibiot
misus
icu
book
rule
antibiot
tri
use
second
rule
tri
use
mani
inappropri
antibiot
treatment
overus
antibiot
contribut
emerg
antibiotic-resist
bacteria
self-prescrib
antibiot
exampl
misus
mani
antibiot
frequent
prescrib
treat
symptom
diseas
respond
antibiot
like
resolv
treatment
incorrect
suboptim
antibiot
prescrib
certain
bacteri
infect
overus
antibiot
like
penicillin
erythromycin
associ
emerg
antibiot
resist
sinc
1950s
widespread
usag
antibiot
hospit
associ
increas
bacteri
strain
speci
longer
respond
treatment
common
antibiot
common
form
antibiot
misus
includ
excess
use
prophylact
antibiot
travel
failur
medic
profession
prescrib
correct
dosag
antibiot
basi
patient
weight
histori
prior
use
form
misus
includ
failur
entir
prescrib
cours
antibiot
incorrect
dosag
administr
failur
rest
suffici
recoveri
inappropri
antibiot
treatment
exampl
prescript
treat
viral
infect
common
cold
one
studi
respiratori
tract
infect
physician
like
prescrib
antibiot
patient
appear
expect
multifactori
intervent
aim
physician
patient
reduc
inappropri
prescript
antibiot
sever
organ
concern
antimicrobi
resist
lobbi
elimin
unnecessari
use
antibiot
issu
misus
overus
antibiot
address
format
interag
task
forc
antimicrobi
resist
task
forc
aim
activ
address
antimicrobi
resist
coordin
center
diseas
control
prevent
food
drug
administr
fda
nation
institut
health
nih
agenc
ngo
campaign
group
antibiot
work
franc
antibiot
automat
govern
campaign
start
2002
led
mark
reduct
unnecessari
antibiot
prescript
especi
children
emerg
antibiot
resist
prompt
restrict
use
uk
1970
swann
report
1969
eu
ban
use
antibiot
growth-promot
agent
sinc
2003
moreov
sever
organ
includ
world
health
organ
nation
academi
scienc
u.s.
food
drug
administr
advoc
restrict
antibiot
use
food
anim
product
howev
common
delay
regulatori
legisl
action
limit
use
antibiot
attribut
resist
regul
industri
use
sell
antibiot
time
requir
research
test
causal
link
use
resist
two
feder
s.
742
h.r.
2562
aim
phase
nontherapeut
use
antibiot
food
anim
propos
pass
endors
public
health
medic
organ
includ
american
holist
nurs
associ
american
medic
associ
american
public
health
associ
apha
despit
pledg
food
compani
restaur
reduc
elimin
meat
come
anim
treat
antibiot
purchas
antibiot
use
farm
anim
increas
everi
year
extens
use
antibiot
anim
husbandri
unit
state
question
emerg
antibiotic-resist
bacteri
strain
use
antibiot
livestock
rais
food
drug
administr
fda
1977
march
2012
unit
state
district
court
southern
district
new
york
rule
action
brought
natur
resourc
defens
council
order
fda
revok
approv
use
antibiot
livestock
violat
fda
regul
histori
befor
earli
20th
centuri
treatment
infect
base
primarili
medicin
folklor
mixtur
antimicrobi
properti
use
treatment
infect
describ
2,000
year
ago
mani
ancient
cultur
includ
ancient
egyptian
ancient
greek
use
special
select
mold
plant
materi
extract
treat
infect
use
antibiot
modern
medicin
began
discoveri
synthet
antibiot
deriv
dye
synthet
antibiot
deriv
dye
synthet
antibiot
chemotherapi
scienc
develop
antibacteri
began
germani
paul
ehrlich
late
1880s
ehrlich
note
certain
dye
color
human
anim
bacteri
cell
wherea
did
propos
idea
possibl
creat
chemic
act
select
drug
bind
kill
bacteria
harm
human
host
screen
hundr
dye
various
organ
1907
discov
medicin
use
drug
synthet
antibacteri
salvarsan
arsphenamin
era
antibacteri
treatment
began
discoveri
arsenic-deriv
synthet
antibiot
alfr
bertheim
ehrlich
1907
ehrlich
bertheim
experi
various
chemic
deriv
dye
treat
trypanosomiasi
mice
spirochaeta
infect
rabbit
earli
compound
toxic
ehrlich
sahachiro
hata
japanes
bacteriologist
work
erlich
quest
drug
treat
syphili
achiev
success
606th
compound
seri
experi
1910
ehrlich
hata
announc
discoveri
drug
606
congress
intern
medicin
wiesbaden
hoechst
compani
began
market
compound
end
1910
salvarsan
drug
known
arsphenamin
drug
use
treat
syphili
half
20th
centuri
1908
ehrlich
receiv
nobel
prize
physiolog
medicin
contribut
immunolog
hata
nomin
nobel
prize
chemistri
1911
nobel
prize
physiolog
medicin
1912
1913
sulfonamid
activ
antibacteri
drug
prontosil
develop
research
team
led
gerhard
domagk
1932
1933
bayer
laboratori
ig
farben
conglomer
germani
domagk
receiv
1939
nobel
prize
physiolog
medicin
sulfanilamid
activ
drug
prontosil
patent
alreadi
use
dye
industri
year
prontosil
relat
broad
effect
gram-posit
cocci
enterobacteria
research
stimul
apac
success
discoveri
develop
sulfonamid
drug
open
era
antibacteri
penicillin
natur
antibiot
observ
growth
microorgan
inhibit
growth
microorgan
report
sinc
late
19th
centuri
observ
antibiosi
microorgan
led
discoveri
natur
antibacteri
loui
pasteur
observ
interven
antagon
observ
bacteria
offer
perhap
greatest
hope
therapeut
1874
physician
sir
william
robert
note
cultur
mold
penicillium
glaucum
use
make
type
blue
chees
did
display
bacteri
contamin
1876
physicist
john
tyndal
contribut
field
pasteur
conduct
research
bacillus
anthraci
grow
presenc
relat
mold
penicillium
notatum
1895
vincenzo
tiberio
italian
physician
publish
paper
antibacteri
power
extract
mold
1897
doctor
student
ernest
duchesn
submit
dissert
contribut
à
l'étude
la
concurr
vital
chez
les
micro-organism
antagonism
entr
les
moisissur
les
microb
contribut
studi
vital
competit
micro-organ
antagon
mold
microb
known
scholar
work
consid
therapeut
capabl
mold
result
anti-microbi
activ
thesi
duchesn
propos
bacteria
mold
engag
perpetu
battl
surviv
duchesn
observ
e.
coli
elimin
penicillium
glaucum
grown
cultur
observ
inocul
laboratori
anim
lethal
dose
typhoid
bacilli
togeth
penicillium
glaucum
anim
did
contract
typhoid
unfortun
duchesn
armi
servic
degre
prevent
ani
research
duchesn
die
tuberculosi
diseas
treat
antibiot
1928
sir
alexand
fleme
postul
exist
penicillin
molecul
produc
certain
mold
kill
stop
growth
certain
kind
bacteria
fleme
work
cultur
disease-caus
bacteria
notic
spore
green
mold
penicillium
chrysogenum
one
cultur
plate
observ
presenc
mold
kill
prevent
growth
bacteria
fleme
postul
mold
secret
antibacteri
substanc
penicillin
1928
fleme
believ
antibacteri
properti
exploit
chemotherapi
initi
character
biolog
properti
attempt
use
crude
prepar
treat
infect
unabl
pursu
develop
aid
train
chemist
ernst
chain
howard
florey
edward
abraham
succeed
purifi
penicillin
penicillin
g
1942
did
becom
wide
avail
outsid
alli
militari
befor
1945
later
norman
heatley
develop
extract
techniqu
effici
purifi
penicillin
bulk
chemic
structur
penicillin
propos
abraham
1942
later
confirm
dorothi
crowfoot
hodgkin
1945
purifi
penicillin
display
potent
antibacteri
activ
wide
rang
bacteria
low
toxic
human
furthermor
activ
inhibit
biolog
constitu
pus
unlik
synthet
sulfonamid
develop
penicillin
led
renew
interest
search
antibiot
compound
similar
efficaci
safeti
success
develop
penicillin
fleme
accident
discov
develop
therapeut
drug
chain
florey
share
1945
nobel
prize
medicin
fleme
florey
credit
rene
dubo
pioneer
approach
deliber
systemat
search
antibacteri
compound
led
discoveri
gramicidin
reviv
florey
research
penicillin
1939
coincid
start
world
war
ii
dubo
report
discoveri
natur
deriv
antibiot
tyrothricin
compound
20
gramicidin
80
tyrocidin
b.
brevi
one
commerci
manufactur
antibiot
veri
effect
treat
wound
ulcer
dure
world
war
ii
gramicidin
howev
use
becaus
toxic
tyrocidin
prove
toxic
usag
research
result
obtain
dure
period
share
axi
alli
power
dure
world
war
ii
limit
access
dure
cold
war
etymolog
term
antibiosi
mean
life
introduc
french
bacteriologist
jean
paul
vuillemin
descript
phenomenon
exhibit
earli
antibacteri
drug
antibiosi
describ
1877
bacteria
loui
pasteur
robert
koch
observ
airborn
bacillus
inhibit
growth
bacillus
anthraci
drug
later
renam
antibiot
selman
waksman
american
microbiologist
1942
term
antibiot
use
1942
selman
waksman
collabor
journal
articl
describ
ani
substanc
produc
microorgan
antagonist
growth
microorgan
high
dilut
definit
exclud
substanc
kill
bacteria
produc
microorgan
gastric
juic
hydrogen
peroxid
exclud
synthet
antibacteri
compound
sulfonamid
current
usag
term
antibiot
appli
ani
medic
kill
bacteria
inhibit
growth
regardless
medic
produc
microorgan
term
antibiot
deriv
anti
+
βιωτικός
biōtiko
fit
life
live
come
βίωσις
biōsi
way
life
βίος
bio
life
term
antibacteri
deriv
greek
ἀντί
anti
+
βακτήριον
baktērion
diminut
βακτηρία
baktēria
staff
cane
becaus
bacteria
discov
rod-shap
research
altern
increas
bacteri
strain
resist
convent
antibacteri
therapi
togeth
decreas
number
new
antibiot
current
develop
drug
pipelin
prompt
develop
bacteri
diseas
treatment
strategi
altern
convent
antibacteri
non-compound
approach
product
classic
antibacteri
agent
target
bacteria
approach
target
host
includ
phage
therapi
vaccin
investig
combat
problem
resist
modifi
agent
one
strategi
address
bacteri
drug
resist
discoveri
applic
compound
modifi
resist
common
antibacteri
resist
modifi
agent
capabl
complet
suppress
bacteri
resist
mechan
exampl
resistance-modifi
agent
inhibit
multidrug
resist
mechan
drug
efflux
cell
increas
suscept
bacteria
antibacteri
target
includ
efflux
inhibitor
phe-arg-β-naphthylamid
beta-lactamas
inhibitor
clavulan
acid
sulbactam
metabol
stimuli
sugar
help
erad
certain
type
antibiotic-toler
bacteria
metabol
activ
vaccin
vaccin
reli
immun
modul
augment
vaccin
excit
reinforc
immun
compet
host
ward
infect
lead
activ
macrophag
product
antibodi
inflamm
classic
immun
reaction
antibacteri
vaccin
respons
drastic
reduct
global
bacteri
diseas
vaccin
attenu
cell
lysat
replac
larg
reactogen
cell-fre
vaccin
consist
purifi
compon
includ
capsular
polysaccharid
conjug
protein
carrier
inactiv
toxin
toxoid
protein
phage
therapi
phage
therapi
anoth
method
treat
antibiotic-resist
strain
bacteria
phage
therapi
infect
pathogen
bacteria
virus
bacteriophag
host
rang
extrem
specif
certain
bacteria
disturb
host
organ
intestin
microflora
unlik
antibiot
bacteriophag
known
simpli
phage
infect
kill
bacteria
affect
bacteri
growth
primarili
dure
lytic
cycl
phage
insert
dna
bacterium
transcrib
use
make
new
phage
cell
lyse
releas
new
phage
abl
infect
destroy
bacteria
strain
high
specif
phage
protect
good
bacteria
destruct
howev
disadvantag
use
bacteriophag
exist
bacteriophag
harbour
virul
factor
toxic
gene
genom
identif
gene
similar
known
virul
factor
toxin
genom
sequenc
prudent
prior
use
addit
oral
iv
administr
phage
erad
bacteri
infect
pose
higher
safeti
risk
topic
applic
addit
concern
uncertain
immun
respons
larg
antigen
cocktail
consider
regulatori
hurdl
clear
therapi
use
bacteriophag
replac
antimicrobi
agent
mdr
pathogen
longer
respond
convent
antibiot
remain
attract
option
despit
numer
challeng
phytochem
plant
import
sourc
antimicrobi
compound
tradit
healer
long
use
plant
prevent
cure
infecti
diseas
recent
renew
interest
use
natur
product
identif
new
member
antibiotic-om
defin
natur
product
antibiot
activ
applic
antibacteri
drug
discoveri
genom
era
phytochem
activ
biolog
compon
plant
phytochem
includ
tannin
alkaloid
terpenoid
flavonoid
possess
antimicrobi
activ
antioxid
dietari
supplement
contain
phytochem
polyphenol
grape
seed
extract
demonstr
vitro
anti-bacteri
properti
phytochem
abl
inhibit
peptidoglycan
synthesi
damag
microbi
membran
structur
modifi
bacteri
membran
surfac
hydrophob
modul
quorum
sens
increas
antibiot
resist
recent
year
potenti
new
plant-deriv
antibiot
investig
new
antibiot
develop
infecti
diseas
societi
america
idsa
report
weak
antibiot
pipelin
doe
match
bacteria
increas
abil
develop
resist
idsa
report
note
number
new
antibiot
approv
market
year
declin
identifi
seven
antibiot
gram-neg
bacilli
gnb
current
phase
2
phase
3
clinic
trial
drug
howev
did
address
entir
spectrum
resist
gnb
accord
fifti
one
new
therapeut
entiti
ntes
antibiot
includ
combin
phase
1-3
clinic
trial
2017
recent
entri
clinic
pipelin
target
multidrug-resist
gram-posit
pathogen
improv
treatment
option
market
approv
new
antibiot
class
oxazolidinon
cyclic
lipopeptid
howev
resist
antibiot
certain
like
occur
need
develop
new
antibiot
pathogen
remain
high
prioriti
recent
drug
develop
target
gram-neg
bacteria
focus
re-work
exist
drug
target
specif
microorgan
specif
type
resist
antibiot
receiv
market
author
seven
year
cephalosporin
ceftarolin
lipoglycopeptid
oritavancin
telavancin
treatment
acut
bacteri
skin
skin
structur
infect
community-acquir
bacteri
pneumonia
lipoglycopeptid
dalbavancin
oxazolidinon
tedizolid
approv
use
treatment
acut
bacteri
skin
skin
structur
infect
new
class
narrow
spectrum
macrocycl
antibiot
fidaxomicin
approv
treatment
c.
difficil
coliti
new
cephalosporin-lactamas
inhibitor
combin
approv
includ
ceftazidime-avibactam
ceftolozane-avibactam
complic
urinari
tract
infect
intra-abdomin
infect
streptomyc
research
expect
provid
new
antibiot
includ
treatment
mrsa
infect
resist
common
use
medic
effort
john
inn
centr
univers
uk
support
bbsrc
result
creation
spin-out
compani
exampl
novacta
biosystem
design
type-b
lantibiotic-bas
compound
nvb302
phase
1
treat
clostridium
difficil
infect
possibl
improv
includ
clarif
clinic
trial
regul
fda
furthermor
appropri
econom
incent
persuad
pharmaceut
compani
invest
endeavor
antibiot
develop
advanc
patient
treatment
adapt
act
introduc
aim
fast
track
drug
develop
antibiot
combat
grow
threat
superbug
act
fda
approv
antibiot
antifung
treat
life-threaten
infect
base
smaller
clinic
trial
cdc
monitor
use
antibiot
emerg
resist
publish
data
fda
antibiot
label
process
suscept
test
interpret
criteria
microbi
organ
breakpoint
provid
accur
data
healthcar
profession
accord
allan
coukel
senior
director
health
program
pew
charit
trust
allow
drug
develop
reli
smaller
dataset
clarifi
fda
author
toler
higher
level
uncertainti
drug
make
risk/benefit
calcul
adapt
make
clinic
trial
feasibl
refer
<ref>
{
{
cite
journal
last1
=
gould
first1
=
k
titl
=
antibiot
prehistori
present
day
journal
=
journal
antimicrobi
chemotherapi
date
=
2016
volum
=
71
issu
=
3
page
=
572-575
url
=
https://doi.org/10.1093/jac/dkv484
accessd
=
20
februari
2019
}
read
extern
link
antibiot
curli
antibiot
portal
